New York State Common Retirement Fund Has $6.26 Million Position in Exelixis, Inc. $EXEL

New York State Common Retirement Fund decreased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 12.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,947 shares of the biotechnology company’s stock after selling 19,510 shares during the period. New York State Common Retirement Fund owned 0.05% of Exelixis worth $6,256,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Byrne Asset Management LLC boosted its holdings in Exelixis by 129.0% in the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 400 shares during the last quarter. Family Legacy Financial Solutions LLC bought a new position in Exelixis during the 2nd quarter worth approximately $33,000. Harbour Investments Inc. lifted its position in shares of Exelixis by 900.0% in the 1st quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 990 shares during the period. Steph & Co. bought a new stake in shares of Exelixis in the 2nd quarter valued at $44,000. Finally, Hantz Financial Services Inc. boosted its stake in shares of Exelixis by 940.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 1,025 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Transactions at Exelixis

In related news, EVP Dana Aftab sold 48,383 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total value of $2,056,277.50. Following the transaction, the executive vice president directly owned 664,778 shares in the company, valued at $28,253,065. This trade represents a 6.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the sale, the director owned 21,380 shares of the company’s stock, valued at $896,463.40. This trade represents a 53.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 245,235 shares of company stock valued at $10,490,600 over the last ninety days. Company insiders own 2.82% of the company’s stock.

Analyst Ratings Changes

EXEL has been the subject of a number of analyst reports. HC Wainwright lifted their target price on shares of Exelixis from $46.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Wells Fargo & Company decreased their price target on Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a report on Tuesday, October 21st. Cowen reissued a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. The Goldman Sachs Group initiated coverage on Exelixis in a research report on Wednesday, September 17th. They set a “buy” rating and a $47.00 target price on the stock. Finally, Leerink Partners upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.45.

Exelixis Price Performance

Shares of EXEL opened at $44.36 on Friday. Exelixis, Inc. has a one year low of $31.90 and a one year high of $49.62. The company has a market cap of $11.89 billion, a PE ratio of 18.72, a P/E/G ratio of 0.80 and a beta of 0.40. The stock has a 50-day moving average of $40.71 and a 200-day moving average of $40.89.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.47 EPS. Analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.